VEGFA and age-related macular degeneration: Advanced neovascular AMD is treated successfully by antivascular endothelial cell growth factor (anti-VEGF) antibodies3,4; however, up to one fourth of wet-AMD patients are unresponsive to anti-VEGF based treatments, and another one third of the initial responders become resistant to the drug after multiple dosages over time.5